Cargando…

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

BACKGROUND: The FAST study identified claudin-18 (CLDN18.2) as a promising novel therapeutic target for gastric cancer (GC). However, the tumor immune microenvironment and clinicopathological features of CLDN18.2-positive GC are unclear, making it difficult to develop and optimize CLDN18.2-targeted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Keren, Chen, Yang, Sun, Yu, Hu, Yajie, Jiao, Lei, Ma, Jie, Yuan, Jiajia, Qi, Changsong, Li, Yanyan, Gong, Jifang, Gao, Jing, Zhang, Xiaotian, Li, Jian, Zhang, Cheng, Shen, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272556/ https://www.ncbi.nlm.nih.gov/pubmed/35811317 http://dx.doi.org/10.1186/s12916-022-02421-1

Ejemplares similares

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
por: Wang, Canming, et al.
Publicado: (2023)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
por: Chen, Jinxia, et al.
Publicado: (2023)

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
por: Liang, Jie, et al.
Publicado: (2021)

CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
por: Kim, Seo Ree, et al.
Publicado: (2020)

Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”
por: Li, Cuicui, et al.
Publicado: (2023)

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

2367: Defining critical features of the immune microenvironment in melanoma using multiplex immunohistochemistry and spatial analysis
por: Gartrell, Robyn, et al.
Publicado: (2018)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment
por: Chen, Yang, et al.
Publicado: (2022)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
por: Qi, Changsong, et al.
Publicado: (2022)

Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family
por: Gao, Peipei, et al.
Publicado: (2021)

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
por: Halse, H., et al.
Publicado: (2018)

Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry
por: Huang, Yu-Kuan, et al.
Publicado: (2019)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

Bright-Field Multiplex Immunohistochemistry Assay for Tumor Microenvironment Evaluation in Melanoma Tissues
por: Ugolini, Filippo, et al.
Publicado: (2022)

ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
por: Konno, Hiroyasu, et al.
Publicado: (2022)

Analysis of the expression and genetic alteration of CLDN18 in gastric cancer
por: Li, Jian, et al.
Publicado: (2020)

Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma
por: Zhang, Zhenfa, et al.
Publicado: (2013)

The IL1β-HER2-CLDN18/CLDN4 axis mediates lung barrier damage in ARDS
por: Ma, Xinhua, et al.
Publicado: (2020)

Defining the Tumor Microenvironment by Integration of Immunohistochemistry and Extracellular Matrix Targeted Imaging Mass Spectrometry
por: Rujchanarong, Denys, et al.
Publicado: (2021)

Brightfield multiplex immunohistochemistry with multispectral imaging
por: Morrison, Larry E., et al.
Publicado: (2020)

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
por: Huang, Yufan, et al.
Publicado: (2023)

The tumor microenvironment in gastrointestinal adenocarcinomas revealed a prognostic and immunotherapeutic biomarker
por: Zhang, Yong, et al.
Publicado: (2022)

Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma
por: Ilié, Marius, et al.
Publicado: (2018)

Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
por: Carbone, Antonino, et al.
Publicado: (2019)

Analysis of Immune Microenvironment by Multiplex Immunohistochemistry Staining in Different Oral Diseases and Oral Squamous Cell Carcinoma
por: Qiao, Bin, et al.
Publicado: (2020)

Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment
por: Boisson, Anaïs, et al.
Publicado: (2021)

The Expression of CLDN6 in Hepatocellular Carcinoma Tissue and the Effects of CLDN6 on Biological Phenotypes of Hepatocellular Carcinoma Cells
por: Lu, Yan, et al.
Publicado: (2021)

Defining an evolutionarily conserved role of GW182 in circular RNA degradation
por: Jia, Ruirui, et al.
Publicado: (2019)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

CLDN1 regulates trophoblast apoptosis and proliferation in preeclampsia
por: Zhang, Yu-chen, et al.
Publicado: (2021)

The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
por: Yan, Hongkai, et al.
Publicado: (2022)

Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications
por: Kwon, Mi Jeong, et al.
Publicado: (2010)

Formulation strategies in immunotherapeutic pharmaceutical products
por: Zhang, Yajie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hes49b4120nhj4d418afabqkif